At the news
? BULLISHIMPACT 5/10 COURT-RULING filed Aug 10, 2026 at 20:00 ET
The court denied Amgen's motion to remand the aflibercept (Eylea) patent litigation back to the Central District of California, keeping the MDL in the Northern District of West Virginia. This is a procedural win for Regeneron, preserving the court's familiarity with the patents and avoiding a restart in a new forum. The ruling maintains the current litigation trajectory, which has already seen all other defendants settle, leaving Amgen as the sole remaining defendant in the MDL.
- Amgen's motion for suggestion of remand was DENIED.
- The MDL (1:24-MD-3103) concerns Regeneron's biologic Eylea (aflibercept) patents.
- All other defendants in the MDL have settled, leaving only Amgen.
- The court cited its familiarity with the case and the inefficiency of remand as reasons for denial.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access